<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Robert M Califf on Medium]]></title>
        <description><![CDATA[Stories by Robert M Califf on Medium]]></description>
        <link>https://medium.com/@califf001?source=rss-850ffb44245------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/0*WMvKQiCzIoX3fZ0d.jpeg</url>
            <title>Stories by Robert M Califf on Medium</title>
            <link>https://medium.com/@califf001?source=rss-850ffb44245------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Sat, 21 Nov 2026 10:15:56 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@califf001/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[The Next Phase of the Pandemic]]></title>
            <link>https://califf001.medium.com/the-next-phase-of-the-pandemic-2b1c7baeae75?source=rss-850ffb44245------2</link>
            <guid isPermaLink="false">https://medium.com/p/2b1c7baeae75</guid>
            <category><![CDATA[covid19]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[testing]]></category>
            <category><![CDATA[vaccines]]></category>
            <dc:creator><![CDATA[Robert M Califf]]></dc:creator>
            <pubDate>Tue, 23 Feb 2021 22:01:55 GMT</pubDate>
            <atom:updated>2021-02-23T22:01:55.691Z</atom:updated>
            <content:encoded><![CDATA[<p>We are now entering a phase in which the widespread distribution of vaccines to combat SARS CoV-2 (coronavirus) is not in question. We’re approaching 2 million people a day vaccinated in the U.S. and 3 million is a reasonable target as manufacturing facilities continue to scale and distribution systems become more efficient. At the same time, there is no doubt that the complex system of manufacturing, distribution and injection will require time for full deployment.</p><p>During this phase, the appropriate allocation of vaccines to people at highest risk (elderly and medical comorbidities) makes sense. But this plan will leave a large proportion of adults and children at the back of line, perhaps going without vaccination until late spring or summer. Universities and schools will be managing a mixed population of vaccinated and unvaccinated people for six months to a year. And since a significant portion of the employed population is younger and healthier, management of the workplace will be a key issue.</p><p>In addition, we are experiencing the anxiety that comes from the realization that coronavirus mutates and that some of these mutations lead to increased infection spread, increased clinical risk or partial or complete “escape” from the currently available vaccines. We cannot take for granted that simply rolling out the current batch of vaccines will solve the problem. Most experts believe that SARS CoV-2 will become “endemic”, meaning that it will be part of our medical concern for a long time to come.</p><p>So, what do employers and people who are not at the front of the line need to consider?</p><p><strong>Don’t break the line for vaccination, but when your turn comes, move quickly</strong></p><p>The orderly rollout of the vaccine is critical. As the data about risk is increasingly combined with the database for who has been vaccinated, rollout teams can work through the wait list with increasing efficiency. Once we have vaccinated the elderly and groups at high medical risk, employers, churches, neighborhood groups, educational institutions and health systems should work together to create a compelling societal mission to vaccinate the population. This will take a combination of science education, enthusiasm and discipline with particular attention to the profound disparities in current vaccination rates. One way of thinking about this would be to think: when your turn comes, move quickly, but also go out of your way to help others move quickly.</p><p><strong>Continue non-pharmaceutical interventions (NPIs)</strong></p><p>Masking, social distancing and better ventilation until the pandemic is under control will be essential. Given the difficulty with “pandemic fatigue”, it’s essential that we focus on the critical behaviors that really matter. We have good evidence that consistent messaging has an effect. See the change in mask wearing between November and now below.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*ROweE5StxmwlcT_x" /><figcaption>Institute for Health Metrics and Evaluation. <a href="http://www.healthdata.org/covid">http://www.healthdata.org/covid</a>. Feb 2021.</figcaption></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*WqMl8G7cyx0N-HvS" /><figcaption>Institute for Health Metrics and Evaluation. <a href="http://www.healthdata.org/covid">http://www.healthdata.org/covid</a>. Feb 2021.</figcaption></figure><p>As we learn more, we can focus the message to reduce wasted effort on ineffective practices like incessantly scrubbing down surfaces. We can also expect the government to make higher quality masks available to reduce inadvertent spread and to work diligently with state and federal governments to be consistent in policies and messaging.</p><p><strong>Testing will continue as a key part of the landscape</strong></p><p>Diagnosis is essential when people are sick, especially now that we know that multiple treatments have been proven to be effective (especially<a href="https://jamanetwork.com/journals/jama/fullarticle/2776307"> monoclonal antibodies for high-risk patients</a>). Testing can identify people who have Covid-19 so they can be routed to effective treatments and isolated from others during their contagious phase.</p><p>We need to increase awareness that testing has another critical role — enabling us to return to more normal activities (i.e. school, work, social activities) safely. The science and technology is continuing to evolve and much less expensive tests, combined with better science like pooled testing, will enable us to sample populations and catch outbreaks early to guide effective contact tracing. This testing strategy will evolve and get more systematic over the next few months and the <a href="https://www.whitehouse.gov/briefing-room/legislation/2021/01/20/president-biden-announces-american-rescue-plan/">Covid rescue plan</a>, when funded, will allocate significant funding to enhance testing capacity.</p><p>A strategic approach to testing will be critical to battle the emergence of variants. If we can detect the variants quickly, we can develop specific antibodies for treatment and modified vaccines for prevention. Different strategies will be needed for individual households, workplaces and schools, and these strategies will need adjustment based on community prevalence and transmission dynamics, specifics of the workplace and evolution of the technology.</p><p>Low cost and rapid turnaround antigen tests will be useful for detecting outbreaks and more accurate PCR tests will be well-suited for systematic evaluation of schools and workplaces. In systematic testing, pooled samples can be used to reduce costs. Another form of testing that is gaining evidence is waste-water testing to measure the overall level and genetic composition of the virus in a geographic area.</p><p><strong>Support schools</strong></p><p>There is a bipartisan political consensus that we need schools to open up, particularly for younger children. While there is serious debate about how quickly we can do this and how to protect teachers, we should reach an agreement soon about how to proceed. As the new cases continue to diminish and vaccinations accelerate, we should be able to vaccinate teachers and school workers and invest in infrastructure in schools to make them safer with better ventilation and spacing. An investment in public school infrastructure will pay off in many ways for the future.</p><p><strong>Track the combination of vaccination and previous infection</strong></p><p>At every level our goal should be to stay as safe as possible while reaching a point where the combination of vaccination and prior infection exceeds 70–90% of the population. This is a useful depiction:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*oDhaSyGjOniR2oTm" /><figcaption>Via Youyang Gu, <a href="https://covid19-projections.com/">https://covid19-projections.com/</a>. Feb 2021.</figcaption></figure><p>The looming issue is the impact of variants due to mutations in the virus that enable it to “escape” the vaccines and can lead to re-infection in people who were previously infected with the older variants. We are familiar with this scenario — it’s the way the flu affects us every year. Previous episodes of the flu do not totally prevent us from being infected again, nor do flu vaccines totally prevent new infections, but immunity reduces the risk of serious negative outcomes.</p><p>We can all do our part with friends and family, but there is also an important role for employers, school administrators and leaders of organizations to continue to optimize vaccination rates, ensure adherence to NPIs and employ judicious use of testing as we gradually resume activities.</p><p>As we hope for the scenario to return to nearly normal activity over the next 3–4 months, we need to prepare for a longer-term coexistence with the virus. The government and scientific community are now investing heavily in platforms that can produce updated vaccines, antibody and antiviral treatments. We need to do our part with preventive measures, vaccination and testing, supporting schools and supporting each other.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=2b1c7baeae75" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Complete, Rapid Reporting of Clinical Trials: A Necessary Component of the Pandemic Response]]></title>
            <link>https://califf001.medium.com/complete-rapid-reporting-of-clinical-trials-a-necessary-component-of-the-pandemic-response-aa158eb1a1cb?source=rss-850ffb44245------2</link>
            <guid isPermaLink="false">https://medium.com/p/aa158eb1a1cb</guid>
            <category><![CDATA[clinical-trials]]></category>
            <category><![CDATA[pandemic]]></category>
            <category><![CDATA[reporting]]></category>
            <category><![CDATA[covid19]]></category>
            <dc:creator><![CDATA[Robert M Califf]]></dc:creator>
            <pubDate>Mon, 04 Jan 2021 15:17:19 GMT</pubDate>
            <atom:updated>2021-01-04T15:32:58.275Z</atom:updated>
            <content:encoded><![CDATA[<p><em>With Deborah A. Zarin, MD, program director, Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard</em></p><p>Health professionals and the general public wake up every morning to a blast of information about the pandemic and possible treatments to either prevent infection or improve outcomes in those who are infected. While opinions and speculation abound, we need results from well-controlled randomized clinical trials adequately powered to enable reliable conclusions about the benefits and harms of treatment options. And — as with most things we’ve learned in this pandemic — the faster we have answers, the better.</p><p>For years, we have been involved in the development and evolution of ClinicalTrials.gov, a place where clinical trials are registered and the results can be recorded. A series of laws and policies require that most clinical trials (with certain exceptions) be registered at study initiation; in addition, in the U.S., certain trials are required to post their summary results within 1–3 years (depending on various factors) of study completion. These policies are designed to ensure that all studies report their results; standards and quality control processes are in place so that the reported results are complete and not misleading. There are penalties for lack of compliance, and although reporting has been imperfect, <a href="https://www.statnews.com/2018/01/09/clinical-trials-reporting-nih/">it is improving</a>. There are now results for over 45,000 studies, about half of which do not have associated publications.</p><p>Rapid dissemination of results is especially critical during a pandemic. In an ideal world, each set of study results would be made available to inform future research, clinical or policy decisions. However, this can only happen if study results are reported accurately, completely and within a relevant timeframe. Results from studies of possible treatments for COVID-19 are especially critical, given the high stakes involved. Of 558 interventional clinical trials with at least one U.S. site assessing medical products for treatment or prevention of COVID-19 registered on ClinicalTrials.gov, 36 have been reported as completed or terminated (26 completed, 10 terminated) and results are only available in ClinicalTrials.gov for 3 (2 completed, 1 terminated). Pre-print servers and press releases accelerate the dissemination of results from some trials, but we know from decades of research that such relatively uncontrolled methods of study dissemination tend to be selective and potentially misleading. Full peer-reviewed publications of results are only linked in ClinicalTrials.gov for 28% of the completed or terminated COVID trials. Despite the promise of eventual widespread vaccination, hospitals are currently at (or past) capacity with COVID patients who need treatment now. The earliest COVID trial results would be “due” in ClinicalTrials.gov a year from now — clearly too late to help the millions of people who will need treatment while we are waiting.</p><p>As we make decisions about what treatments are recommended and how to plan for the next trials, access to complete and reliable results is critical. If only dramatic results are available, there is a risk of misunderstanding the total picture of evidence about a treatment. Furthermore, new research studies should be informed by the landscape of all relevant completed and ongoing trials as they occur. If not, multiple trials could be initiated that are addressing the same question, or that are addressing questions for which we already know the answer. This can <a href="https://jamanetwork.com/journals/jama/article-abstract/2740057">cause harm by unnecessarily burdening those trial participants</a> or create opportunity costs by not having participants recruited into potentially more valuable studies — an especially detrimental effect during a pandemic when patient volunteers are greatly needed for rapid recruitment into trials with large enough sample sizes and high-quality design to produce reliable results.</p><p>The requirement for trial registration has allowed us to track the explosion of COVID-19 clinical trials since the pandemic began.</p><p><strong><em>Figure: Number of COVID-19 Studies Posted at ClinicalTrials.gov, by Funder Type</em></strong></p><figure><img alt="Chart showing the Number of COVID-19 Studies Posted at ClinicalTrials.gov, by Funder Type" src="https://cdn-images-1.medium.com/max/1024/1*b82RGzoUsGZfg2gv7xKXew.jpeg" /></figure><p>2,243 COVID-19 interventional clinical trials were registered on Clinical Trials.gov as of Dec 1, 2020; 558 were treatment or prevention trials with at least one US site<strong>. </strong>As <a href="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2768882?resultClick=1">Krumholz has reported</a>, many of these studies are small and unlikely to yield definitive results when considered alone. In addition, the <a href="https://doi.org/10.1177/1740774520972082">lack of upfront coordination</a> hinders efforts to combine data from studies that use different outcome measures in different populations.</p><p>In contrast, the <a href="https://clinicaltrials.gov/ct2/show/NCT04381936">RECOVERY trial</a> provides an excellent example of the power of coordination when more than 170 sites come together taking advantage of every opportunity for a trial participant to contribute. The program answered several critical therapeutic questions quickly and has moved on to testing additional therapies.</p><p>A simple search of ClinicalTrials.gov prior to study design and initiation could help to solve problems like trial duplication and inefficiency. Researchers and sponsors could use the search results to inform their choice of study question and avoid inventing a new study design or outcome measure when a “common” or “standard” is already evolving. Gaps in the research landscape could more readily be filled while avoiding unnecessary duplication of existing or completed research.</p><p>An issue of immediate importance that calls for active coordination is the use of therapeutic antibodies. EUAs have been granted for <a href="https://www.fda.gov/media/143603/download">bamlanivimab</a> and <a href="http://fda.gov/media/143892/download">casirivimab + imdevimab</a> because of definitive results in small trials showing a reduction in symptoms and need for hospitalization. However, multiple questions remain unanswered and the <a href="https://www.wsj.com/articles/why-are-covid-antibody-drugs-sitting-on-shelves-11608499832">current use of therapeutic antibodies is suboptimal</a>. Traditionally, industry would fund studies that are designed to support marketing applications or new indications, while, over time, the academic and clinical practice community would address issues necessary to inform clinical decision making. This system may or may not be “good enough” in normal times, but it is not producing the right array of clinical trials that are needed right now to address urgent clinical questions.</p><p><strong><em>Table: SARS-CoV2 Interventional Monoclonal Antibody Studies with &gt;/=1 U.S. site</em></strong></p><figure><img alt="Table showing SARS-CoV2 Interventional Monoclonal Antibody Studies with &gt;/=1 U.S. site" src="https://cdn-images-1.medium.com/max/1024/1*qt8XE6OE3KY1xoFhHpto3w.jpeg" /></figure><p>Given the time frame in which we need to understand additional issues about dosing, comparative effectiveness and patient selection for therapeutic antibodies, there may be a need for more central control over the prioritization and conduct of trials in this arena.</p><p>There is <a href="https://www.federalregister.gov/documents/2016/09/21/2016-22129/clinical-trials-registration-and-results-information-submission">a part of FDAAA</a> that authorizes the Secretary of HHS to require results reporting within 30 days if it is “necessary to protect the public health” — the public health emergency that we are currently experiencing should satisfy this criterion. Of course, researchers and sponsors could simply choose to report their results rapidly. In fact, the NIH set a good example when <a href="https://clinicaltrials.gov/ct2/show/results/NCT04280705?recrs=eh&amp;rslt=With&amp;type=Intr&amp;cond=COVID-19&amp;cntry=US&amp;draw=2&amp;rank=4">NIAID posted results for the ACTT trial within 127 days of its completion</a> — long before the results were due. And the NIH overall <a href="https://www.nih.gov/about-nih/who-we-are/nih-director/statements/nih-calls-clinical-researchers-swiftly-share-covid-19-results?utm_medium=email&amp;utm_source=govdelivery">has encouraged grantees to report more quickly</a> to ClinicalTrials.gov. The numbers, however, suggest that such voluntary action is rare. We urge HHS, the FDA and NIH to use this provision of FDAAA, as well as other tools available to them, to get study results into ClinicalTrials.gov as rapidly as possible; this will improve the ability of our clinical trials system to reliably and efficiently answer key questions essential to optimize treatment in the midst of this crisis.</p><p>There are multiple efforts underway examining the use of common platforms<em> </em>to optimize the design of protocols for therapies attempting to treat the same diseases or specific health problems. In the meantime, we urge sponsors and investigators to use ClinicalTrials.gov to inform landscape analyses prior to starting new studies, and to post their study results as rapidly as possible so that they are available to inform research, clinical and policy decisions.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=aa158eb1a1cb" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The Workplace Transformed: Balancing Safety and Personal Autonomy as We Return to Work and School]]></title>
            <link>https://califf001.medium.com/the-workplace-transformed-balancing-safety-and-personal-autonomy-as-we-return-to-work-and-school-95352dee4121?source=rss-850ffb44245------2</link>
            <guid isPermaLink="false">https://medium.com/p/95352dee4121</guid>
            <category><![CDATA[testing]]></category>
            <category><![CDATA[symptoms]]></category>
            <category><![CDATA[return-to-work]]></category>
            <category><![CDATA[community]]></category>
            <category><![CDATA[covid19]]></category>
            <dc:creator><![CDATA[Robert M Califf]]></dc:creator>
            <pubDate>Thu, 23 Jul 2020 21:10:57 GMT</pubDate>
            <atom:updated>2020-07-23T21:10:57.058Z</atom:updated>
            <content:encoded><![CDATA[<p><em>With Vivian Lee, President, Verily Health Platforms and Vindell Washington, Chief Clinical Officer, Verily Health Platforms</em></p><p>The COVID-19 pandemic has dramatically altered daily life and makes returning to normal an enormous challenge. The virus tests our ability to participate in our most cherished activities, from eating at restaurants to working out at the gym. Most pressing now is the return to work and school, as employment and education are among the most important drivers of our economy and sense of well-being, both future and present, and organizations are grappling with how to return safely. Because many infected individuals are asymptomatic and can unknowingly spread COVID-19, there is no simple way to identify who may be placing others at risk. Accordingly, a thoughtful strategy is needed as we return to essential activities for our social, economic and intellectual well-being.</p><p>Before we return to campuses and offices, our day-to-day activities and spaces must be redesigned. Verily’s work with communities, public health officials, and educational and business leaders has revealed the need for a comprehensive program that integrates multiple sources of information to inform and deploy these return programs. To meet that need, Verily has embarked on <a href="https://verily.com/stories/healthyatwork/">Healthy at Work</a>, which includes COVID-19 testing, daily symptom screening, population analytics and ongoing safety controls. The program includes a simple user interface through which employees or students can track their symptoms and set up tests, as well as surfaces data-driven insights to employers and administrators to support ongoing decision-making and safety.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*7FfDmNigCbxWPmIjfpxjRA.jpeg" /><figcaption>Introducing Healthy at Work</figcaption></figure><p><em>Evaluating tradeoffs</em></p><p>As we have designed Healthy at Work, we have engaged with experts and institutions facing inevitable trade-offs. People want:</p><ul><li>Privacy</li><li>The right to live without disability caused by illness, and</li><li>Physical freedom, including the ability to work.</li></ul><p>These values cannot easily be satisfied at the same time during the pandemic because the virus is best contained by extreme limitation of interaction and social activity. Accordingly, we are working with businesses and educational institutions who are putting in the hard work to design return to work and school policies, allowing as much freedom as possible while protecting people’s health and personal information.</p><p>Each business and school has unique circumstances. And each organization is part of a community that has its own specific needs. A technology company, a university and a manufacturing facility, for example, all have different risk factors and will likely need different approaches to mitigate those risks. A business in a high-transmission area will have increased risks and a need for more testing compared to a business in a lower transmission area.</p><p>Our decision to enter this arena was based on years of work at the intersection of health, technology and analysis intended to improve health outcomes. Most notably, <a href="http://www.verily.com/healthyatwork">Healthy at Work</a> is informed by our <a href="https://www.projectbaseline.com/study/covid-19/">Baseline COVID-19 Program</a>, which started as an effort to assist the state of California with community based testing and has now evolved to testing over 500,000 people in over 140 locations across the United States, including an option to volunteer for research. It also borrows the approach of <a href="http://www.verily.com/pathfinder">Verily Pathfinder</a>, our programmable web application for symptom checking, based on CDC guidelines. People appreciate user-friendly systems that enable convenient scheduling and feedback, and many people are interested in contributing to research that can help others deal with the pandemic. Additionally, while technology can make a big difference, implementation of testing and risk assessment is dependent upon a collaborative relationship among the many people whose lives are affected by the results and the actions we take.</p><p>While Verily took these factors into account when building Healthy at Work as a program in which we all learn together, Verily also complies with state and federal guidelines. Governments and their public health officials have authority over reopening strategies because each business is a part of a larger community with the health of that entire community at stake. If an outbreak occurs within a local business, the effects will be felt well beyond that business. The Baseline Covid-19 Program, focused on <a href="https://blog.verily.com/2020/04/health-disparities-covid-19-underserved-communities.html">community based testing</a> has taught us about the benefits of coordinated activity between public health and business, so that the most effective decisions can be made based on evolving data.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/950/1*KYMp_7Obs510_yeDluc45g.png" /><figcaption>PCR testing at a Project Baseline site</figcaption></figure><p><em>Steps forward</em></p><p>Given that reopening regulations vary at a federal and state level, corporate and educational leaders and industry experts must work together to establish a strategy and best practices for returning to shared spaces — one that fits their circumstances and community — while mitigating as much risk as possible. This risk is based on many factors including:</p><ul><li>The type of work performed</li><li>The physical layout of a given work space</li><li>The prevalence and transmission rates of COVID-19 in the community</li></ul><p>We believe that empirical observations linked to statistical modeling will be critical to helping calculate various risks and estimating the benefits of testing strategies and specific interventions in the workplace or school. We have developed algorithms that take into account coronavirus-related risks, and how testing strategies will best inform risk assessment so that institutions can consider and decide on appropriate interventions. Healthy at Work is designed so that the algorithms will improve as we implement the program and learn from our experiences — we’re paralleling efforts from organizations like the CDC in using data to inform decision-making.</p><p>For example, if the virus is spreading quickly in a given community, people may be more likely to become infected from home than from the workplace. This means more stringent social distancing at work will be necessary, but not sufficient; more frequent testing would be needed to detect asymptomatic people bringing infection risk from home to the workplace. Since we’re all learning about this new virus, we plan to keep the public informed as we enhance our testing strategies and programs, through our <a href="http://blog.verily.com/">blog</a> and publications.</p><p>We’re using our background in laboratory science and testing workflows to contribute to the global effort to develop better, less expensive tests; optimize the strategy for who should be tested; and determine how tests should be conducted. With more testing comes new challenges, such as wait times and lab processing, but we must commit to continuing this essential action to combat the pandemic. We do expect the specific strategies for testing to be tailored to the local characteristics of the epidemic, the specific needs of a business or school and the evolving quality, costs and turn-around time of tests.</p><p>But health risks are not the only concerns. We must also be careful and diligent about data privacy and protection. Adhering to legal standards is essential, but not enough.</p><p>We are committed to effective approaches to privacy, confidentiality, and the ethics of this complex situation as the program is implemented. Our corporate <a href="https://verily.com/our-story/privacy/">approach to privacy</a> is publicly posted and we’re working with a team of skilled internal and external experts to evolve it to meet the needs of the industry and our constituents.</p><p>We want to ensure that we’re not only following the latest guidance from the Centers for Disease Control and Prevention, the Food and Drug Administration, and state and local authorities, but also meeting the highest level of ethical conduct in this program that is operating in a complex and evolving environment. Our engagement with publicly available efforts like the <a href="https://muse.jhu.edu/book/75831">Johns Hopkins report on the ethics of contact tracing</a> will continue.</p><p>We are optimistic about our Healthy at Work program, but also recognize the complexity, the uncertainties and the magnitude of the issues we’re endeavoring to address. We plan to continue working closely with employers, educators, employees, students and public health experts. We’ll use scientifically-backed research to help Americans and their families safely return to work and school at a pace dictated by the evidence.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=95352dee4121" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Customizing the Sharing of Health Data]]></title>
            <link>https://califf001.medium.com/customizing-the-sharing-of-health-data-f34c30cce609?source=rss-850ffb44245------2</link>
            <guid isPermaLink="false">https://medium.com/p/f34c30cce609</guid>
            <category><![CDATA[sxsw]]></category>
            <category><![CDATA[research]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[clinical-research]]></category>
            <dc:creator><![CDATA[Robert M Califf]]></dc:creator>
            <pubDate>Wed, 07 Mar 2018 16:04:25 GMT</pubDate>
            <atom:updated>2018-03-07T16:04:25.085Z</atom:updated>
            <content:encoded><![CDATA[<h4>The ecosystem benefits when people have more than just ownership of their health data</h4><p>This 2017 holiday season, fitness trackers and genetic testing kits <a href="http://money.cnn.com/2017/12/26/news/companies/amazon-christmas-holidays/index.html">flew off the virtual shelves</a>. We are entering a time when our physical, digital and biological spheres are merging, a concept that has been called “<a href="https://www.weforum.org/agenda/2016/01/the-fourth-industrial-revolution-what-it-means-and-how-to-respond/">the 4th Industrial Revolution</a>”, and healthcare and clinical research are at a critical point of evolution. New technologies enable the <a href="https://healthitanalytics.com/news/nih-preps-national-launch-of-all-of-us-precision-medicine-biobank">collection of deeper and wider datasets</a> that hold the promise of surfacing new insights into the biology and behavioral genesis of health and disease.</p><p>We are simultaneously experiencing a paradigm shift, <a href="https://www.elsevier.com/connect/Dr-Eric-Topol-Digital-healthcare-will-put-the-patient-in-charge">championed by Dr. Eric Topol</a>, <a href="https://www.fastcompany.com/2679963/the-cofounder-of-23andme-on-the-future-of-personal-data-tracking">Linda Avey</a> and others, in our understanding of health data ownership. Cultural expectations, bolstered <a href="https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/access/index.html">by the law</a>, are leading us to an understanding that individuals own and should control their health information.</p><p>While organizations and advocates collectively work on this quest, we also must consider that access and control is not enough. For people and their families, there is a range of personal capabilities and motivations to actively engage in the full spectrum of their health information. For those of us who provide clinical care and conduct research there is an obligation to consider the preferences of the patient or research participant and to make this information meaningful. In addition, the vast majority of people receive care through general practitioners or specialty clinicians in health systems, and if a result triggers a clinical concern it will be critical to coordinate the communication of information.</p><p>Consumer-facing devices have begun to move in the direction of offering curated health data, characterizing general health status of an individual through a few physiological measurements. Much will be learned from the experience of returning information in the consumer environment focused on maintenance of health. At the same time, clarification of people’s right to their health records has led to a requirement that electronic health records are accessible through a portal, with penalties for not doing so. This will provide another source of learning about how to share information that was previously considered the private purview of doctors and health systems.</p><p><a href="http://www.verily.com/">Verily</a> is engaged in <a href="http://www.projectbaseline.com/">Project Baseline</a>, which is stretching beyond previous boundaries to create a biomedical information system that can measure the spectrum from biomolecular (as in genetics), clinical (including imaging, lab testing and health outcomes), behavioral, social and environmental data (collected through sensors, wearable devices like watches and cell phones). Working in partnership with participants in North Carolina and California to start, we are developing this system through detailed measurement of a diverse population. As we address the return of results beyond health maintenance or clinical care into research measurements, we are aware of the challenge and opportunity to share results in a way that comports with participants’ capabilities and wishes as well as with those who care for them. And there are a lot of results to parse — over 6 terabytes of data generated in the first 2 days of an individual’s participation in the study.</p><p>In order to return the data that participants offer back to them, the experience must be meaningful. We are exploring ways to do this in a manner that does not create unnecessary anxiety or concern, and that helps people take appropriate, timely action ultimately enhancing the relationship between study participants and their clinicians.</p><p>Take my specialty of cardiovascular medicine. In the Project Baseline study we are doing an echocardiogram in the first 1000 participants. This detailed image of the heart produces hundreds of complex measurements and holds the promise of new knowledge by integrating the image interpretation with the other detailed measurements. Only a small proportion of Baseline participants would want the detailed summary, and many “abnormalities” are common and require no clinical intervention. In other cases we may discover an abnormality that most clinicians agree require the most serious type of medical intervention, such as valve surgery. These results from our study are not in the context of a clinical test ordered for a specific reason and putting results in context often requires interaction with a clinician.</p><p>Project Baseline is on the cutting edge of these issues. We will be adapting and learning as we go, but the principles of personal right to information and partnership in the joy of research discovery with research participants, their families and communities are guiding lights in our journey. But we are also highly attuned to the need to work on this partnership with sensitivity to the needs, well-being and preferences of participants. The combination of the human skills and technology of Verily, our academic partners and the research participants themselves should create a roadmap for personalization of return of results.</p><p>We will be discussing what we are learning and debating the path forward at South by Southwest’s <a href="https://schedule.sxsw.com/2018/events/PP77989">Empowering people to own their health data</a> this Saturday, March 10 at 9.30am and welcome comments as we learn how to navigate this exciting change in our view of health and the use of information to maintain it.</p><p><em>Robert Califf, MD</em></p><p><em>Advisor, Verily; Vice Chancellor for Clinical and Translational Research, Duke University; Former Commissioner, US Food and Drug Administration</em></p><p>This post is also available on Verily’s <a href="https://blog.verily.com/2018/03/customizing-sharing-of-health-data.html">blog</a>.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=f34c30cce609" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>